Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors

Pharmacological Reviews

Volumn 51, Issue 4, 1999, Pages 593-628

  Männistö, Pekka T ^a   Kaakkola, Seppo ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; APOMORPHINE; DOBUTAMINE; ENTACAPONE; FENOLDOPAM; ISOPRENALINE; LEVODOPA; METHYLDOPA; NITECAPONE; RIMITEROL; TOLCAPONE;

DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENTIATION; DYSKINESIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ESTROGEN METABOLISM; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS;

EID: 0038287034     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (372)

1. Acquas E, Carboni E, Deree RHA, Da Prada M and Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neuroehem 59:326-330.
2. Adler CH, Singer C, OBrien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D and Yoo K (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 55:1089-1095.
3. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT and Hämäläinen E (1994a) Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86:1076-1082.
4. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Höckerstedt K, Wähälä K, Hase T, Hämäläinen E and Fotsis T (1994b) Diet and urinary estrogen profile in various populations: A preliminary report. Polycyclic Arom Comp 6:261-273.
5. Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinävaara S, Karlsson M, Wikberg T, Tuomainen P and Männistö PT (1995) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa/carbidopa in volunteers. Clin Neuropharmacol 18:46-57.
6. Assal F, Spahr L, Hadengue A, Rubbiabrandt L and Burkhard P (1998) Tolcapone and fulminant hepatitis. Lancet 352:958.
7. Axelrod J, Senoh S and Witkop B (1958) O-Methylation of catechol amines in vivo. J Biol Chem 233:697-701.
8. Axelrod J and Tomchick R (1958) Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 233:702-705.
9. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G, Auff E, Volc D, Dupont E, Mikkelsen B, Wermuth L, Worm-Petersen J, Benecke R, Eichhom T, Kolbe H, Oertel W, Schimrigk K, Olsson JE, Palhagen S, Burgunder JM, Ghika A, Regli F, Steck A and Medcalf P (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63:421-428.
10. Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Lindén I-B, Männistö PT, Kaakkola S and Pohto P (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 32:841-846.
11. Baldessarini RJ (1987) Neuropharmacology of S-adenosyl-L-methionine. Am J Med 83:95-103.
12. Ball P, Emons G, Haupt O, Hoppen H-O aad Knuppen R (1978) Radioimmunoassay of 2-hydroxy-estrone. Steroids 31:249-258.
13. Ball P and Knuppen R (1980) Catecholestrogens (2-and 4-hydroxyoestrogens): Chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol 93 (Suppl 232):1-127.
14. Ball P, Knuppen R, Haupt M and Breuer H (1972) Interactions between estrogens and catechol amines. III. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the catechol-O-methyltransferase. J Clin Endocrinol Metab 34:736-746.
15. Ball P, Reu G, Schwab J and Knuppen R (1979) Radioimmunoassay of 2-hydroxyestrone and 2-methoxyestrone in human urine. Steroids 33:563-576.
16. Bamsdah J (1969) Catechol O-methyltransferase in epidermis, dermis and whole skin. J Invest Dermatol 52:351-352.
17. Banger M, Hiemke C, Knuppen R, Ball P, Haupt M and Wiedeman K (1990) Formation and metabolism of catecholestrogens in depressed patients. Biol Psychiatry 28:685-696.
18. Barnea ER and Avigdor S (1990) Coordinated induction of estrogen hydroxylase and catechol-O-methyl transferase by xenobiotics in 1st trimester human placental explants. J Steroid Biochem 35:327-331.
19. Benson R, Crowell B, Hill B, Doonquah K and Charlton C (1993) The effects of L-dopa on the activity of methionine adenosyltransferase: Relevance to L-dopa therapy and tolerance. Neurochem Res 18:325-330.
20. 11C-labelled L-DOPA. Nucl. Med Biol 24:15-19.
21. Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm HW and Malherbe P (1991) Human catechol-O-methyltransferase: Cloning and expression of the membrane-associated form. Proc Natl Acad Sci USA 88:1416-1420.
22. Bieck PR, Antonin K-H, Farger G, Nilsson EB, Schmidt EK, Dostert P, Benedetti MS and Waldmeier PC (1993) Clinical pharmacology of the new COMT inhibitor CGP 28014. Neurochem Res 18:1163-1167.
23. Bieck PR, Nilsson E and Antonin KH (1990) Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J Neural Transm Suppl 32:387-391.
24. BIOMED European Bipolar Collaborative Group (1997) No association between bipolar disorder and alleles at a functional polymorphism in the COMT gene. Br J Psychiatry 170:526-528.
25. Borges N, Vieira-Coelho MA, Parada A and Soares-da-Silva P (1997) Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 282:812-817.
26. Borgulya J, Bruderer H, Bernauer K, Zürcher G and Da Prada M (1989) Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: Synthesis and structure-activity studies. Helv Chim Acta 72:952-968.
27. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schläppl B and Zürcher G (1991) Ro 40-7592 (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone), catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 16:719-721.
28. Boudikova B, Szumlanski C, Maidak B and Weinshilboum R (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48:381-389.
29. Bradlow HL, Herschcopf RJ and Fishman J (1986) Oestradiol 16α-hydroxylase: A risk marker for breast cancer. Cancer Surv 5:573-583.
30. Bradlow HL, Michnovicz JJ, Telang NT and Osborne MP (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12:1571-1574.
31. Bradlow HL, Sepkovic DW, Telang NT and Osborne MP (1995) Indole-3-carbinol: A novel approach to breast cancer prevention. Ann NY Acad Sci 768:180-200.
32. Brannan T, Martinez-Tica J and Yahr MD (1992) Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: An in vivo study in rats. Neurology 42:683-685.
33. Brannan T, Prikhojan A and Yahr MD (1997) Peripheral and central inhibitors of catechol-O-methyl transferase: Effects on liver and brain COMT activity and L-DOPA metabolism. J Neural Transm Gen Sect 104:77-87.
34. Bryan-Lluka LJ (1995) Evidence for saturation of catechol-O-methyltransferase by low concentrations of noradrenaline in perfused lungs of rats. NaunynSchmiedeberg's Arch Pharmacol 361:408-416.
35. Budygin EA, Gainetdinov RR, Kilpatrick MR, Rayevsky KS, Männistö PT and Wightman RM (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur J Pharmacol 370:125-131.
36. Bui QD and Weisz J (1988) Monooxygenase mediating catecholestrogen formation by rat anterior pituitary is an estrogen-4-hydroxylase. Endocrinology 124:1085-1087.
37. Buu NT (1985) Dopamine sulfoconjugation in the rat brain: Regulation by monoamine oxidase. J Neurochem 45:470-476.
38. Cass WA, Zahniser NR, Flach KA and Gerhardt GA (1993) Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of locally applied uptake inhibitors. J Neurochem 61:2269-2278.
39. Cavalieri EL and Rogan EG (1998) Role of aromatic hydrocarbons in disclosing how catecholestrogens initiate cancer, in Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine (Goldstein DS, Eisenhofer G and McCarty R eds) pp 837-840, Academic Press, San Diego.
40. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL and Rogan EG (1997) Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94:10937-10942.
41. Cedarbaum JM, Leger G and Guttman M (1991) Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease. Clin Neuropharmacol 14:330-342.
42. Charlton CG (1997) Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: A model that may explain the occurrence of depression in Parkinson's disease. Life Sci 61:495-502.
43. Chen CH, Lee YR, Liu MY, Wei FC, Koong FJ, Hwu HG and Hsiao KJ (1996) Identification of a BglI polymorphism of catechol-O-methyltransferase (COMT) gene, and association study with schizophrenia. Am J Med Genet 67:556-559.
44. Cohn CK and Axelrod J (1971) The effect of estradiol on catechol-O-methyltransferase activity in rat liver. Life Sci 10:1351-1354.
45. Coudoré F, Durif F, Duroux E, Eschalier A and Fialip J (1997) Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport 8:877-880.
46. Cumming P, Brown E, Damsma G and Fibiger H (1992) Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: An in vivo microdialysis study. J Neurochem 69:1905-1914.
47. Cushman M, He HM, Katzenellen-Bogan JA, Lin CM and Hamel E (1995) Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38:2041-2049.
48. D'Amato RJ, Lin CM, Flynn E, Folkman J and Hamel E (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91:3964-3968.
49. Daniels JK, Williams NM, Williams J, Jones LA, Gardno AG, Murphy KC, Spurlock G, Riley B, Scambler P, Asherson P, McGuffin P and Owen MJ (1996) No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry 153:268-270.
50. Dannan GA, Porubek DJ, Nelson SD, Waxman DJ and Guengerich FP (1986) 17β-Estradiol 2-and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: Roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement. Endocrinology 118:1952-1960.
51. Da Prada M, Borgulya J, Napolitano A and Zürcher G (1994) Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenoayl-L-methionine-sparing effect. Clin Neuropharmacol 17 (Suppl 3): S26-S37.
52. Da Prada M, Keller HH, Pieri L, Kettler R and Haefely WE (1984) The pharmacology of Parkinson's disease: Basic aspects and recent advances. Experientia (Basel) 40:1165-1172.
53. Da Prada M, Zürcher G, Kettler R and Colzi A (1991) New therapeutic strategies in Parkinson's disease: Inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592, in Basal Ganglia III (Bernardi G, Carpenter M, Di Chiara G and Stanzione P eds) pp 723-732, Plenum Press, New York.
54. Davis TL, Kurth MC, Saint-Hilaire MH, Trosch RM, Charles PD, LeWitt P, Pedder S, Dorflinger E and Jorga K (1997) Effects of tolcapone withdrawal after 6 week treatment in Parkinsonian patients who exhibit end-of-dose wearing off (Abstract). Mov Disord 12 (Suppl 1):97.
55. Davis TL, Roznoski M and Burns RS (1995a) Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 18:333-337.
56. Davis TL, Roznoski M and Burns RS (1995b) Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 10:349-351.
57. Deleu D, Sarre S, Ebinger G and Michotte Y (1995) The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: An in vivo microdialysis study. J Pharmacol Exp Ther 273:1323-1331.
58. De Santi C, Donatelli P, Giulianotti PC, Pietrabissa A, Mosca F and Pacifici GM (1998a) Interindividual variability of histamine N-methyltransferase in the human liver and kidney. Xenobiotica 28:571-577.
59. De Santi C, Giulianotti PC, Pietrabissa A, Mosca F and Pacifici GM (1998b) Catechol-O-methyltransferase: Variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol 54:215-219.
60. 18F]Ro41-0960. Life Sci 58:195-208.
61. Dingemanse J (1997) Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease. Drug Dev Res 42:1-25.
62. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M and van Brummelen P (1995a) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57:508-517.
63. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T and van Brummelen P (1996) Multiple dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 50:47-55.
64. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M and van Brummelen P (1995b) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262.
65. 18F]L-DOPA. Eur J Pharmacol 334: 31-38.
66. Dunn JF (1983) Transport of estrogens in human plasma, in Catechol Estrogens (Merriem GR and Lipsett MB eds) pp 167-176, Raven Press, New York.
67. Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E, Beiske A, Findley L, Godwin-Austen R, Hess CW, Horne M, Larsen JP, Ekstedt B, Mikkelsen B, Palhagen S, Palm R, Tysnes OB, vanderLinden C and Wermuth L (1997) Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study. Mov Disord 12:928-934.
68. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A and Lenders JWM (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83:2175-2185.
69. Ekblom J, Aquilonius S-M and Josaan SS (1993) Differential increases in catecholamine metabolizing enzymes in amyotrophic lateral sclerosis. Exp Neurol 123: 289-294.
70. Ekblom J, Garpenstrand H, Tottmar O, Prince J and Oreland L (1998) A cell culture model of cerebral ischemia as a convenient system to screen for neuroprotective drugs. J Neural Transm Suppl 52:93-98.
71. +-ATPase. Kidney Int 62:742-747.
72. European Medicine Evaluation Agency (1998) Press release: Recommendation for the suspension of the marketing authorization for Tasmar (tolcapone), London.
73. Emons G, Ball P and Knuppen R (1983) Radioimmunoassays of catecholestrogens, in Catecholestrogens (Merriam GR and Lipsett MB eds) pp 71-81, Raven Press, New York.
74. Emons G, Merriam R, Pfeiffer D, Loriaux DL, Ball P and Knuppen R (1987) Metabolism of exogenous 4-and 2-hydroxyestradiol in human male. J Steroid Biochem 28:499-504.
75. Ericsson AD (1971) Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 14:193-197.
76. Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A and Neve KA (1997) Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. J Neurochem 69:1459-1466.
77. Etemadzadeh E, Koskinen L and Kaakkola S (1989) Computerized rotometer apparatus for recording circling behavior. Meth Find Exp Clin Pharmacol 11:399-407.
78. Fahn S (1974) "On-off" phenomenon with levodopa therapy in parkinsonism: Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 24:431-441.
79. Feigelson HS and Henderson BE (1996) Estrogens and breast cancer. Carcinogenesis 17:2279-2284.
80. Fernandes MH and Soares-da-Silva P (1994) Role of monoamine oxidase and catechol-O-methyltransferase in the metabolism of renal dopamine. J Neural Transm Suppl 41:101-105.
81. 18F]-fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48:1077-1082.
82. 18F]-fluoro L-dopa in human blood. J Nucl Med 29:363-369.
83. Fishman J and Martucci C (1979) Absence of measurable catechol estrogens in the rat brain-evidence for rapid turnover. J Clin Endocrinol Metab 49:940-942.
84. Fishman J and Martucci CP (1980) Biological properties of 16α-hydroxyestrone: Implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 51:611-615.
85. Fishman J, Osborne MP and Telang NT (1995) The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 768:91-100.
86. Flemström G and Säfsten B (1994) Role of dopamine and other stimuli of mucosal bicarbonate secretion in duodenal protection. Dig Dis Sci 39:1839-1842.
87. Flemström G, Säfsten B and Jedstedt G (1993) Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds. Gastroenterology 104:825-833.
88. Fotsis T (1987) The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS. II. Fractionation and quantitation of the main groups estrogen conjucates. J Steroid Biochem 28:215-226.
89. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP and Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature (Lond) 368:237-239.
90. Franks S, MacLusky NJ and Naftolin F (1982) Comparative pharmacology of oestrogens and catecholestrogens: Actions on the immature uterus in vivo and in vitro. J Endocrinol 94:91-98.
91. Fredriksson A and Archer T (1995) Synergistic interactions between COMT-/MAO-inhibitors and L-dopa in MPTP-treated mice. J Neural Transm Gen Sect 102:19-34.
92. Friedgen B, Wölfel R and Graefe KH (1996a) The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines. Naunyn-Schmiedeberg's Arch Pharmacol 353:193-199.
93. Friedgen B, Wolfel R, Russ H, Schomig E and Graefe KH (1996b) The role of extraneuronal amine transport systems for the removal of extracellular catecholamines in the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 354:275-286.
94. Fujioka M (1992) Mammalian small molecule methyltransferases: Their structural and functional features. Int J Biochem 24:1917-1924.
95. Funaki T, Onodera H, Ushiyama N, Tsukamoto Y, Tagami C, Fukazawa H and Kuruma I (1994) The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats. J Pharm Pharmacol 46:571-574.
96. Funaki T, Onodera H, Ushiyama N, Tsukamoto Y, Tagami C, Fukazawa H and Kuruma I (1995) Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats. J Pharm Pharmacol 47:539-542.
97. Garris PA and Wightman RM (1995) Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse 20:269-279.
98. Gasparini M, Fabrizio E, Bonifati V and Meco G (1997) Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm Gen Sect 104:887-894.
99. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D and Karayiorgou M (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95:9991-9996.
100. Gordin A, Huupponen R, Rouru J, Korpela K, Huhtala S and Reinikainen K (1998a) Pharmacokinetics of entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of entacapone and effect on levodopa metabolism. Eur J Neurol 5 (Suppl 3):S165-S166.
101. Gordin A, Pentikäinen PP, Mäkimartti M and Reinikainen K (1998b) Pharmacokinetics of the COMT inhibitor entacapone in liver failure and the effect of entacapone on liver function (Abstract). Neurology 50 (Suppl 4):387.
102. Grossman MH, Emanuel BS and Budarf ML (1992a) Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1→q11.2. Genomics 12:822-825.
103. Grossman MH, Littrel JB, Weinstein R, Szumlanski C and Weinshilboum RM (1992b) Identification of the possible basis for inherited differences in human catechol-O-methyltransferase (Abstract). Trans Neurosci Soc 18:70.
104. 18F]fluoro-L-dopa in rhesus monkey. Nucl Med Biol 22:921-927.
105. Guimarães JT, Vieira-Coelho MA, Serrão MP and Soares-da-Silva P (1997) Opossum kidney (OK) cells in culture synthesize and degrade the natriuretic hormone dopamine: A comparison with renal tubular cells. Int J Biochem Cell Biol 29:681-688.
106. Guldberg HC and Marsden CA (1975) Catechol-O-methyltransferase: Pharmacological aspects and physiological role. Pharmacol Rev 27:135-206.
107. Gutíerrez B, Bertranpetit J, Guillamat R, Vallès V, Arranz M, Kerwin R and Fañanás L (1997) Association analysis of catechol O-methyltransferase gene and bipolar affective disorder. Am J Psychiatry 154:113-115.
108. Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM and Gjedde A (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 8:298-304.
109. Hamel E, Lin CM, Flynn E and D'Amato RJ (1996) Interaction of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and tubulin polymers. Biochemistry 35:1304-1310.
110. Hansell P, Odlind C and Männistö PT (1998) Different renal effects of two inhibitors of catechol-O-methylation in the rat: Entacapone and CGP 28014. Acta Physiol Scand 162:489-494.
111. Haramaki N, Stewart DB, Aggarwal S, Kawabata T and Packer L (1995) Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury. Biochem Pharmacol 50:839-843.
112. Hardie RJ, Malcolm SL, Lees AJ, Stern GM and Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429-436.
113. 11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography. J Neural Transm Gen Sect 87:15-22.
114. Hauser RA, Molho E, Shale H, Pedder S and Dorflinger EE (1998) A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Mov Disord 13:643-647.
115. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ and Sutter TR (1996) 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93:9776-9781.
116. Heeringa MJ, d'Agostini F, DeBoer P, Da Prada M and Damsma G (1997) Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. J Neural Transm Gen Sect 104:593-603.
117. Heikkinen H, Pentikäinen PJ, Saraheimo M, Ahtila S and Ottoila P (1994) Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: A study using stable isotope technique (Abstract), 11th International Symposium on Parkinson's Diease; March 26-30, Rome. 301 p.
118. Henderson BE, Pike MC, Berstein L and Ross RK (1996) Breast cancer, in Cancer Epidemiology and Revention (Schottenfeld D and Fraumeni JF Jr eds) pp 1022-1039, Oxford University Press, New York.
119. Himori N and Mishima K (1994) The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. Experientia (Basel) 50:939-942.
120. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, AlChalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR and Collier DA (1996) No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 228:780-784.
121. Holden JE, Doudet D, Endres CJ, Chan GLY, Morrison KS, Vingerhoets FJG, Snow BJ, Pate BD, Sossi V, Buckley KR and Ruth TJ (1997) Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase. J Nucl Med 38:1568-1574.
122. Hong J, Shu-Leong H, Tao X and Lap-Ping Y (1998) Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport 9:2861-2864.
123. Hsu C-J, Kirkman BR and Fishman J (1991) Differential expression of oncogenes c-fos, c-myc and neu/Her-2 induced by estradiol and 16alfa-hydroxyestrone in human cancer cell line (Abstract). 73rd Annual Endocrine Society Meeting; Washington DC. 586 p.
124. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S and Gordin A (1994) COMT inhibition by high-dose entacapone does not affect hemodynatnics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharm 32:582-588.
125. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M and Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 58:221-227.
126. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M and Gordin A (1996a) Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 59:450-457.
127. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M and Gordin A (1996b) Simultaneous inhibition of catecholamine O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions. Eur J Clin Pharmacol 51:273-276.
128. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Marouleff C and Eidelberg D (1996) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-863.
129. Jeanjean AP, Laterre EC and Maloteaux JM (1997) Neuroleptic binding to sigma receptors: Possible involvement in neuroleptic-induced acute dystonia. Biol Psychiatry 41:1010-1019.
130. Jeffery D and Roth JA (1984) Characterization of membrane-bound and soluble catechol-O-methyltransferase from human frontal cortex. J Neurochem 42:826-832.
131. Jeffery D and Roth JA (1987) Kinetic reaction mechanism for magnesium binding to membrane-bound and soluble catechol-O-methyltransferase. Biochemistry 26: 2955-2958.
132. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ and Bradlow HL (1993) Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45:1129-1136.
133. Jellinck PH, Michnovicz JJ and Bradlow HL (1991) Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids 56:446-450.
134. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zürcher G and Aitken J (1997a) The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 38:59-67.
135. Jorga K, Fotteler B, Sedek G, Nielsen T and Aitken J (1998b) The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 245:223-230.
136. Jorga K, Fotteler B and van Brummelen P (1997b) Why should tolcapone be given at a lower dose to patients with liver cirrhosis? Clin Pharmacol Ther 61:183.
137. Jorga KM (1998) Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers. Neurology 50 (Suppl 5):S31-S38.
138. Jorga KM, Fotteler B, Heizmann P and Zürcher G (1998a) Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 54:443-447.
139. Jorga KM, Kroodsma JM, Fotteler B, Heizman P, Meyer J, Rasch MC and van Hattum J (1998c) Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 63:646-654.
140. Jorga KM, Sedek G, Fotteler B, Zürcher G, Nielsen T and Aitken JW (1997c) Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 62:300-310.
141. Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ and Rita H (1990) Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-DOPA in healthy volunteers. Clin Neuropharmacol 13:436-447.
142. Kaakkola S, Gordin A and Männistö PT (1994a) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase (COMT). Gen Pharmacol 25:813-824.
143. Kaakkola S, Männistö PT and Nissinen E (1987) Striatal membrane-bound and soluble catechol-O-methyltransferase after selective neural lesions in the rat. J Neural Transm Gen Sect 69:221-228.
144. Kaakkola S, Teräväinen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H and Gordin A (1995) Entacapone in combination with standard or controlled-release levodopa/ carbidopa: A clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 2:341-347.
145. Kaakkola S, Teräväinen H, Ahtila S, Rita H and Gordin A (1994b) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44:77-80.
146. Kaakkola S and Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: A microdialysis study. Brain Res 587:241-249.
147. Kaakkola S and Wurtman RJ (1993) Effects of COMT inhibitors and L-dopa with and without carbidopa on extracellular dopamine in the rat striatum. J Neurochem 60:137-144.
148. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J and Gogos JA (1997) Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 94:4572-4575.
149. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, Kazazian HH, Housman DE and Pulver AE (1998) Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 43:425-431.
150. Karege F, Bovier P, Gaillard J-M and Tissot R (1987) The decrease of erythrocyte catechol-O-methyltransferase activity in depressed patients and its diagnostic significance. Acta Psychiatry Scand 76:303-308.
151. Karhunen T, Tilgmann C, Ulmanen I, Julkunen I and Panula P (1994) Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 42:1079-1090.
152. Karhunen T, Tilgmann C, Ulmanen I and Panula P (1995a) Catechol-O-methyltransferase (COMT) in rat brain: Immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 187: 57-60.
153. Karhunen T, Tilgmann C, Ulmanen I and Panula P (1995b) Neuronal and non-neuronal catechol-O-methyltransferase in primary cultures of rat brain cells. Int J Dev Neurosci 13:825-834.
154. Katajamäki J, Honkanen A, Piepponen TP, Linden IB, Zharkovsky A and Ahtee L (1998) Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats. Pharmacol Biochem Behav 60:23-26.
155. Kelland MD, Freeman AS, Rubin J and Chiodo LA (1993) Ascending afferent regulation of rat midbrain dopamine neurons. Brain Res Bull 31:539-546.
156. Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L and Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145-156.
157. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ,
158. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH and Berthou F (1992) Nature of cytochrome P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 44:1745-1756.
159. Kern C and Bernards CM (1997) Ascorbic acid inhibits spinal meningeal catechol-O-methyltransferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology 86:405-409.
160. Kern C, Mautz DS and Bernards CM (1995) Epinephrine is metabolized by the spinal meninges of monkeys and pigs. Anesthesiology 83:1078-1081.
161. Khromova I, Rauhala P, Zolotov N and Männistö PT (1995) Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the nucleus basalis of Meynert. Neuroreport 6:1219-1222.
162. Khromova I, Voronina T, Kraineva VA, Zolotov N and Männistö PT (1997) Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav Brain Res 88:49-57.
163. Kirov G, Murphy KC, Arranz MJ, Jones I, McCandles F, Kunugi H, Murray RM, McGuffin P, Collier DA, Owen MJ and Craddock N (1998) Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 3:342-345.
164. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ (1997) Inhibition of angiogenesis and breast cancer in mice by microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81-86.
165. Klemetsdal B, Straume B, Giverhaug T and Aarbakke J (1994) Low catechol-O-methyltransferase activity in a Saami population. Eur J Clin Pharmacol 46:231-235.
166. Knutson L, Knutson TW and Flemström G (1993) Endogenous dopamine and duodenal bicarbonate secretion in humans. Gastroenterology 104:1409-1413.
167. Kopin I (1985) Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 37:333-364.
168. Kraychy S and Gallagher TF (1957) 2-Methoxyestrone, a new metabolite of estradiol-17β in man. J Biol Chem 229:519-526.
169. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ and Collier DA (1997a) High and low activity alleles of catechol-O-methyltransferase gene: Ethnic difference and possible association with Parkinson's disease. Neurosci Lett 221:202-204.
170. Kunugi H, Vallada HP, Hoda F, Kirov G, Gill R, Aitchison KJ, Ball D, Arranz MJ, Murray RM and Collier DA (1997b) No evidence for am association of affective disorders with high-or low-activity allele of catechol-O-methyltransferase gene. Biol Psychiatry 42:282-285.
171. Kurth MC, Adler CH, StHilaire M, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Saint-Hilaire M, Pery LM, Thomas C, Turpin L, O'Brien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tanner CM, Kelker K, Lewis P, Trosch RM, Mistura KL, Montgomery EB, Lindsey B, Weiner W, Shulman LM, Sheldon C, Waters CH, Welsh M, Trugman JM, Landow ER, Pedder SCJ, Shimon GS and Magni G (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Neurology 48:81-87.
172. Kuruma I, Bartholini G, Tissot R and Pletscher A (1971) The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 12:678-682.
173. Kuruma I, Bartholini G, Tissot R and Pletscher A (1972) Comparative investigation of inhibitors of extracerebral dopa decarboxylaae in man and rats, J Pharm Pharmacol 24:289-294.
174. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R and Papolos DF (1996a) Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velocardio-facial syndrome. Am J Med Genet 67:468-472.
175. Lachman HM, Nolan KA, Mohr P, Saito T and Volavka J (1998) Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am J Psychiatry 155:835-837.
176. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL and Weinshilboum RM (1996b) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatrie disorders. Pharmacogenetics 6:243-250.
177. 18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition by nitecapone (OR-462). Neurology 42:199-203.
178. Lam LKT (1988) Effects of butylated hydroxyanisole on glutathione S-transferase and catechol-O-methyltransferase activities in Syrian golden hamsters. Biochem Pharmacol 37:3011-3016.
179. Lan EY and Bruice TC (1998) Importance of correlated motions in forming highly reactive near attack conformations in catechol O-methyltransferase. J Am Chem Sec 120:12387-12394.
180. Larsen KR, Dajani EZ, Dajani NE, Dayton MT and Moore JG (1998) Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. Dig Dis Sci 43:1806-1813.
181. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW and Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493-5497.
182. Lee MR (1993) Dopamine and kidney: Ten years on. Clin Sci 84:357-375.
183. Lemon HM, Heidel JW and Rodriguez-Sierra JF (1992) Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer. Cancer Surv 69:457-465.
184. Lepoole IC, Vandenwijngaard RMJGJ, Smit NPM, Oosting J, Westerhof W and Pavel S (1994) Catechol-O-methyltransferase in vitiligo. Arch Dermatol Res 286: 81-86.
185. Levin ED, Mcgurk SR, Rose JE and Butcher LL (1990) Cholinergic-dopaminergic interactions in cognitive performance. Behav Neural Biol 54:271-299.
186. Li JJ and Li SA (1987) Estrogen carcinogenesis in Syrian hamster tissues: Role of metabolism. Fed Proc 46:1858-1863.
187. Li JJ, Li SA, Oberley TD and Parsons JA (1995) Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: Relation to hormonal activity and cell proliferation. Cancer Res 55:4347-4351.
188. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, Liu X and Collier DA (1996) Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiat Genet 6:131-133.
189. Li T, Vallada H, Curtis D, Arranz M, Xu K, Cai GQ, Deng H, Liu J, Murray R, Liu XH and Collier DA (1997) Catechol-O-methyltransferase Val158Met polymorphism: Frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics 7:349-353.
190. Li Y, Zhang G, Suzuki H and Kuriyama H (1991) Actions of dipyridamole on endogenous and exogenous noradrenaline in the dog mesenteric vein. Br J Pharmacol 102:51-56.
191. Li Y-S, Wirth T, Huotari M, Laitinen K, MacDonald E and Männistö PT (1998) No change of brain extracellular catecholamine levels after acute COMT inhibition: A microdialysis study in anaesthetized rats. Eur J Pharmacol 356:127-137.
192. Liehr JG (1990) Genotoxic effects of estrogens. Mutat Res 238:269-276.
193. Liehr JG, Fang WF, Sirbasku DA and Ulubelen AA (1986a) Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 24:353-356.
194. Liehr JG and Roy D (1990) Free radical generation by redox cycling of estrogens. Free Radical Biol Med 8:415-423.
195. Liehr JG, Ulubelen AA and Strobel HW (1986b) Cytochrome P-450-mediated redox cycling of estrogens. J Biol Chem 261:16865-16870.
196. Lier BT, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA and Zhu BT (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 92:9220-9224.
197. Liljequist R, Haapalinna A, Åhlander M, Li Y-H and Männistö PT (1997) Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 82:195-202.
198. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R and Perret JE (1995) Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 18:258-265.
199. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I and Taskinen J (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
200. Lottering M-L, Haag M and Seegers JC (1992) Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52:5926-5932.
201. Lundström K, Salminen M, Jalanko A, Savolainen R and Ulmanen I (1991) Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 10:181-189.
202. Lundström K, Tenhunen J, Tilgmann C, Karhunen T, Panula P and Ulmanen I (1995) Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta Prot Struct Mol Enzymol 1251:1-10.
203. Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P and Teräväinen H (1997) Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease. Mov Disord 12:497-505.
204. MacLusky NJ, Barnea ER, Clark CR and Naftolin F (1983) Catechol estrogens and estrogen receptors, in Catechol Estrogens (Merriam GR and Lipsett MB eds) pp 151-165, Raven Press, New York.
205. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG and Yuasa S (1970) Age at first birth and breast cancer risk. Bull WHO 43:209-221.
206. Maj J, Rogóz Z, Skuza G, Sowinska H and Superata J (1990) Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinsons disease. J Neural Transm Park Dis Dement Sect 2:101-112.
207. Malherbe P, Bertocci B, Caspers P, Zürcher G and Da Prada M (1992) Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J Neurochem 58:1782-1789.
208. Männistö PT (1998) Catechol-O-methyltransferase: Characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors, in Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine (Goldstein D, Eisenhofer G and McCarty R eds) pp 324-328, Academic Press, San Diego.
209. Männistö PT and Kaakkola S (1989) New selective COMT inhibitors: Useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10: 54-56.
210. Männistö PT and Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66:317-323.
211. Männistö PT, Kaakkola S, Nissinen E, Lindén I-B and Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43:1465-1471.
212. Männistö PT, Lang A, Rauhala P, Soosaar A and Vasar E (1995) Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur J Pharmacol 274:229-233.
213. Männistö PT, Tuomainen P and Tuominen RK (1992a) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol 105:569-574.
214. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C and Kaakkola S (1992b) Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39:291-350.
215. Männistö PT, Ulmanen I, Taskinen J and Kaakkola S (1994) Catechol O-methyltransferase (COMT) and COMT inhibitors, in Design of Enzyme Inhibitors as Drugs (Sandler M and Smith HJ eds) pp 625-647, Oxford University Press, Oxford.
216. Marcocci L, Maguire JJ and Packer L (1994) Nitecapone: A nitric oxide radical scavenger. Biochem Mol Biol Intern 34:531-541.
217. Martucci C and Fishman J (1976) Uterine estrogen receptor binding of catecholestrogens and of estetrol (1,3,5(10)estratriene-3,15α,16α,17β-tetrol). Steroids 27:325-333.
218. Maruyama W, Naoi M and Narabayashi H (1996) The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: Analysis of the intraventricular fluid from parkinsonian patients. J Neurol Sci 139:141-148.
219. McGeer EG, Kremer B and Hayden MR (1993) Monoamines and their metabolites in Huntington's disease brain: Evidence for decreased catechol-O-methyltransferase activity. Biol Psychiatry 33: 551-553.
220. McLeod HL, Fang L, Luo XL, Scott EP and Evans WE (1994) Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 270:26-29.
221. McLeod HL, Syvänen AC, Githanga J, Indalo A, Ismail D, Dewar K, Ulmanen I and Sludden J (1998) Ethnic differences in catechol O-methyltransferase pharmacogenetics: Frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 8:195-199.
222. Meister B, Bean AJ and Aperia A (1993) Catechol-O-methyltransferase messenger RNA in the kidney and its appearance during ontogeny. Kidney Int 44:726-733.
223. Merello M, Lees A, Webster R, Bovingdon M and Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltrasferase inhibitor, on the motor response to acute levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57:186-189.
224. Merriam GR, MacLusky NJ, Pickard MK and Naftolin F (1980) Comparative properties of the catechol estrogens. I. Methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids 369:1-11.
225. Merrill RC (1958) Estriol: A review. Physiol Rev 38:463-480.
226. Messiha FS, Hsu TH and Bianchine JR (1972) Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. J Clin Invest 51:452-455.
227. Miletich RS, Comi G, Bankiewicz K, Plunkett R, Adams R, Dichiro G and Kopin IJ (1993) 6-[F-18]Fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res 626:1-13.
228. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J and Joseph JA (1997) Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55-66.
229. Millikan RC, Pittman GS, Tse CKJ, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ and Bell DA (1998) Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 19:1943-1947.
230. Moreau JL, Borgulya J, Jenck F and Martin JR (1994) Tolcapone: A potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 5:344-350.
231. Myllylä VV, Jackson M, Larsen JP and Baas H (1997a) Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: A multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 4:333-341.
232. Myllylä VV, Sotaniemi KA, Illi A, Suominen K and Keränen T (1993) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45:419-423.
233. Myllylä VV, Sotaniemi KA, Mäkimartti M, Korpela K, Kyyrä T, Karlsson M and Gordin A (1997b) Effect of entacapone as an adjunct to Sinemet and Madopar on the pharmacokinetics of levodopa in parkinsonian patients (Abstract). Mov Disord 12 (Suppl 1):103.
234. Napolitano A, Cesura AM and Da Prada M (1995a) The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl 48:35-45.
235. Napolitano A, Zürcher G and Da Prada M (1995b) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur J Pharmacol 273:215-221.
236. Nissinen E, Kaheinen P, Penttilä KE, Kaivola J and Lindén IB (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 340:287-294.
237. Nissinen E, Lindén I-B, Schultz E, Kaakkola S, Männistö PT and Pohto P (1988a) Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur J Pharmacol 153:263-269.
238. Nissinen E, Lindén IB, Schultz E and Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedeberg's Arch Pharmacol 346:262-266.
239. Nissinen E, Tuominen RK, Perhoniemi V and Kaakkola S (1988b) Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 42:2609-2614.
240. Nutt JG and Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-79.
241. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP and Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919.
242. Oechsner M, Sturenburg HJ, Böhmann C, Möller D and Kunze K (1998) Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition (Abstract). Eur J Neurol 5 (Suppl 3):169.
243. Ohara K, Nagai M, Suzuki Y, Ochiai M and Ohara K (1998a) No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiat Res 80:145-148.
244. Ohara K, Nagai M, Suzuki Y and Ohara K (1998b) Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. Neuroreport 9:1305-1308.
245. Ohmori O, Shinkai T, Kojima H, Terao T, Suzuki T, Mita T and Abe K (1998) Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosci Lett 243:109-112.
246. Orama M, Tilus P, Taskinen J and Lotta T (1997) Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J Pharm Sci 86:827-831.
247. Ordonez LA, Arbrus M, Boyson S, Goodman MN, Ruderman NB and Wurtman RJ (1974) Skeletal muscle: Reservoir for exogenous L-dopa. J Pharmacol Exp Ther 190:187-191.
248. Orion (1998) Comtess: Summary of Product Characteristics, Orion Corp., Espoo, Finland.
249. Osborne MP, Telang NT, Kaur S and Bradlow HL (1990) Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse. Steroids 55:114-119.
250. Ovaska M and Yliniemelä A (1998) A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols. J Comput Aided Mol Design 12: 301-307.
251. Papolos DF, Faedda G, Veit S, Goldberg R, Morrow B, Luchepalati R and Shprintzen R (1996) Bipolar spetrum disorders in patients diagnosed with velo-cardio-facial syndrome: Does a hemizygous deletion on chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 153:1541-1547.
252. Papolos DF, Veit S, Faedda GL, Saito T and Lachman HM (1998) Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Mol Psychiatry 3:346-349.
253. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Ann Neurol 42:747-755.
254. Parvez S, Parvez SH and Youdim MBH (1975) Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br J Pharmacol 53:241-246.
255. 18F]fluoro-L-DOPA. Eur J Pharmacol 257:53-58.
256. Pentikäinen PJ, Saraheimo M, Vuorela A, Ottoila P, Kultalahti E-R and Wikberg T (1990) Fate of nitecapone, a new catechol-O-methyltransferase inhibitor in man: A study with double isotope technique (Abstract). Clin Pharmacol Ther 47:156.
257. Pentikäinen PJ, Vuorela A, Järvinen M, Wikberg T and Gordin A (1989) Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor (Abstract). Eur J Clin Pharmacol 36:110.
258. Perez RA, Fernandez-Alvarez E, Nieto O and Piedrafita FJ (1992) Dihydroxynitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: Synthesis and biological activity as catechol-O-methyltransferase inhibitors. J Med Chem 35:4584-4588.
259. Perez RA, Fernandez-Alvarez E, Nieto O and Piedrafita FJ (1993) Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols: Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitrobenzylidene)-2,4-pentanedione. Biochem Pharmacol 45:1973-1981.
260. Perez RA, Fernandez-Alvarez E, Nieto O and Piedrafita FJ (1994) Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2,(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone. J Enzym Inhib 8:123-131.
261. Psylla M, Günther I, Antonini A, Vontobel P, Reist HW, Zollinger A and Leenders KL (1997) Cerebral 6-[F-18]fluoro-L-DOPA uptake in rhesus monkey: Pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res 767:45-54.
262. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E and Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology 49: 1066-1071.
263. Reches A and Fahn S (1984) Catechol-O-methyltransferase and Parkinson's disease. Adv Neurol 40:171-179.
264. Reenilä I, Tuomainen P, Soinila S and Männistö PT (1997) Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci Lett 230:155-158.
265. Reenilä I, Tuomainen P, Tilgmann C and Männistä PT (1995) Opposite effects of ethanol on recombinant membrane-bound and soluble activities of catechol-O-methyltransferase. Pharmacol Toxicol 77:414-416.
266. Reilly DK, Hershey L, Rivera-Calimlim L and Shoulson I (1983) On-off effects in Parkinson's disease: A controlled investigation of ascorbic acid therapy. Adv Neuroi 37:51-60.
267. Reilly DK, Rivera-Calimlim L and Van Dyke D (1980) Catechol-O-methyltransferase activity: A determinant of levodopa response. Clin Pharmacol Ther 28:278-286.
268. Rice PJ, Abraham ST, Huang NY and Doman RJ (1997) Extraneuronal uptake inhibitor U-0521 decreases contractile responses in rat vas deferons. Gen Pharmacol 29:437-439.
269. Riley B, Mogudi-Carter M, Jenkins T and Williamson R (1996) No evidence for linkage of chromosome 22 markers to schizophrenia in Southern African Bantu-speaking families. Am J Med Gen (Neuropsychiat Gen) 67:515-522.
270. Rinne UK, Larsen JP, Siden A and Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309-1314.
271. Rivas E, deCeballos ML, Nieto O and Fontenla JA (1999) In vivo effects of new inhibitors of catechol-O-methyl transferase. Br J Pharmacol 126:1667-1673.
272. Rivera-Calimlim L and Reilly DK (1984) Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: Difference in levodopa tolerance. Clin Pharmacol Ther 36:804-809.
273. Rivera-Calimlim L, Tandon D, Anderson F and Joynt R (1977) The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders: Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 34:228-232.
274. Rivett AJ, Eddy B and Roth JA (1982) Contribution of sulfate conjugation, deamination and O-methylation of dopamine and norepinephrine in human brain. J Neurochem 39:1009-1016.
275. Rivett AJ, Francis A and Roth JA (1983) Distinct cellular localization of membranebound and soluble forms of catechol-O-methyltransferase in brain. J Neurochem 40:215-219.
276. Rivett AJ and Roth JA (1982) Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol-O-methyltransferase. Biochemistry 21: 1740-1742.
277. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM and Chase TN (1993a) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/ carbidopa action in parkinsonian patients. Neurology 43:2685-2688.
278. Roberts JW, Cora-Locatelli G, Bravi D, Metman VL, Mouradian MM and Chase TN (1993b) Catechol-O-methyltransferase (COMT) inhibitor Ro 40-7592 prolongs duration of action of levodopa/carbidopa in parkinsonian patients (Abstract). Neurology (Suppl 2):332.
279. Roche (1997) Tasmar (tolcapone), product monograph. F. Hoffman-La Roche, Basel, Switzerland.
280. Roche (1998) Tasmar: Summary of product characteristics, F. Hoffman-La Roche, Basel, Switzerland.
281. Roth JA (1992) Membrane-bound catechol-O-methyltransferase: A reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120:1-29.
282. Roth JA, Grossman MH and Adolf M (1990) Variation in hepatic membrane-bound catechol-O-methyltransferase activity in Fischer and Wistar-Furth strains of rat. Biochem Pharmacol 40:1151-1153.
283. Ruottinen HM and Rinne UK (1996a) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19:283-296.
284. Ruottinen HM and Rinne UK (1996b) Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222-233.
285. Ruottinen HM and Rinne UK (1996c) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60:36-40.
286. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction. Synapse 27:336-346.
287. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect 10:91-106.
288. Salminen M, Lundström K, Tilgmann C, Savolainen R, Kalkkinen N and Ulmanen I (1990) Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 93:241-247.
289. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology 44:1292-1297.
290. Scanlon PD, Raymond FA and Weinshilboum RM (1979) Catechol-O-methyltransfferase: Thermolabile enzyme in erythrocytes of subjects homozygous for the allele for low activity. Science (Wash DC) 203:63-65.
291. Schultz E and Nissinen E (1989) Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 38:3953-3956.
292. Schultz E, Tarpila S, Bäckström AC, Gordin A, Nissinen E and Pohto P (1991) Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur J Clin Pharmacol 40:577-580.
293. Sedek G, Jorga K, Schmitt M, Burns RS and Leese P (1997) Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 20:531-541.
294. Seegers JC, Aveling M-L, van Aswegen CH, Cross M, Koch F and Joubert WS (1989) The cytotoxic effects of estradiol-17β catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 32:797-809.
295. Sharpless NS, Tyce GM and Owen CA Jr (1973) Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Life Sci 12:97-106.
296. Shibata T, Pavel S, Smit NPM and Mishima Y (1993) Differences in subcellular distribution of catechol-O-methyltransferase and tyrosinase in malignant melanoma. J Invest Derm 100:S222-S225.
297. Shintani F, Kinoshita T, Kanba S, Ishikawa T, Suzuki E, Sasakawa N, Kato R, Asai M and Nakaki T (1996) Bioactive 6-nitronorepinephrine identified in mammalian brain. J Biol Chem 271:13561-13565.
298. Sladek-Chelgren S and Weinshilboum RM (1981) Catechol-O-methyltransferase biochemical genetics: Human lymphocyte enzyme. Biochem Gen 19:1037-1053.
299. Slomiany BL, Liau YH, Lopez RA and Slomiany A (1993) Nitecapone effect on the synthesis and secretion of gastric sulfomucin. Gen Pharmacol 24:69-73.
300. Smit NPM, Latter AJM, Naishbyfield S, Westerhof W, Pavel S and Riley PA (1994) Catechol-O-methyltransferase as a target for melanoma destruction? Biochem Pharmacol 48:743-752.
301. Smit NPM and Pavel S (1995) Induction of cytotoxicity in melanoma cells through inhibition of catechol-O-methyltransferase. Biochem Pharmacol 50:1955-1962.
302. Smith LA, Gordin A, Jenner P and Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12:935-945.
303. Spielman RS and Weinshilboum RM (1981) Genetics of red cell COMT activity: Analysis of thermal stability and family data. Am J Med Genet 10:279-290.
304. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y and Sutter TR (1998) Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19:291-298.
305. Stack DE, Cavalieri EL and Rogan EG (1998) Catecholestrogens as procarcinogens: Depurinating adducts and tumor initiation, in Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine (Goldstein D, Eisenhofer G and McCarty R eds) pp 833-836, Academic Press, San Diego.
306. Steulet A-F, Stöcklin K, Wicki P and Waldmeier P (1993) Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis. Neurochem Res 18:1131-1136.
307. Strous RD, Bark N, Parsia SS, Volavka J and Lachman HM (1997a) Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: Evidence for association with aggressive and antisocial behavior. Psychiat Res 69: 71-77.
308. Strous RD, Bark N, Woerner M and Lachman HM (1997b) Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 41:493-495.
309. Suchar LA, Chang RL, Rosen RT, Lech J and Conney AH (1995) High perfomance liquid chromatography separation of hydroxylated estradiol metabolites: Formation of estradiol metabolites by liver microsomes from male and female rats. J Pharmacol Exp Ther 272:197-206.
310. Sundberg S and Gordin A (1991) COMT inhibition with nitecapone does not affect the tyramine pressor response. Clin Pharmacol 32:130-132.
311. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A and Keränen T (1993a) The effect of the COMT inhibitor entacapone on the haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36:451-456.
312. Sundberg S, Scheinin M, Ojala-Karlsson P, Akkila J and Gordin A (1993b) The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur J Clin Pharmacol 44:287-290.
313. Sundberg S, Scheinin M, Ojala-Karlsson P, Kaakkola S, Akkila J and Gordin A (1990) Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clin Pharmacol Ther 48:356-364.
314. Suzuki YJ, Tsuchiya M, Safadi A, Kagan VE and Packer L (1992) Antioxidant properties of nitecapone (OR-462). Free Radical Biol Med 13:517-525.
315. Syvänen AC, Tilgmann C, Rinne J and Ulmanen I (1997) Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7:65-71.
316. Taskinen J, Wikberg T, Ottoila P, Kanner L, Lotta T, Pippuri A and Bäckström R (1991) Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine. Drug Metab Dispos 19:178-183.
317. Tedroff J, Hartvig P, Bjurling P, Andersson Y, Antoni G and Långström B (1991) Central actions of benserazide after COMT
318. Tenhunen J, Salminen M, Jalanko A, Ukkonen S and Ulmanen I (1993) Structure of the rat catechol-O-methyltransferase gene: Separate promoters are used to produce messenger RNAs for soluble and membrane-bound forms of the enzyme. DNA Cell Biol 12:253-263.
319. Tenhunen J, Salminen M, Lundström K, Kiviluoto T, Savolainen R and Ulmanen I (1994) Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223:1049-1059.
320. Tenhunen J and Ulmanen I (1993) Production of rat soluble and membrane-bound catechol O-methyltransferase forms from bifunctional mRNAs. Biochem J 296: 595-600.
321. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham JR, Laughlin R, Nemoto T, Kadlubar FF and Ambrosone CB (1998) Genetic polymorphism in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58:2107-2110.
322. Tiihonen J, Hallikainen T, Lachman H, Saito T, Volovka J, Kauhanen J, Salonen JT, Ryynänen O-P, Koulu M, Karvonen MK, Pohjalainen T, Syvälahti E and Hietala J (1999) Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 4:286-290.
323. Tilgmann C and Kalkkinen N (1990) Purification and partial characterization of rat liver soluble catechol-O-methyltransferase. FEBS Lett 264:95-99.
324. Tilgmann C and Kalkkinen N (1991) Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta: Comparison to the rat liver enzyme. Biochem Biophys Res Commun 174:995-1002.
325. Tilgmann C, Melen K, Lundström K, Jalanko A, Julkunen I, Kalkkinen N and Ulmanen I (1992) Expression of recombinant human soluble-and membrane-bound catechol-O-methyltransferase in eukaryotic cells and identification of the respective enzymes in rat brain. Eur J Biochem 207:813-821.
326. Tohgi H, Abe T, Yamazaki K, Saheki M, Takahashi S and Tsukamoto Y (1995) Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: Correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 192:165-168.
327. Törnwall M, Kaakkola S, Tuomainen P, Kask A and Männistö PT (1994) Comparison of two new inhibitors of catechol O-methyltransferase on striatal dopamine metabolism: A microdialysis study in rats. Br J Pharmacol 112:13-18.
328. Törnwall M and Männistö PT (1991) Acute toxicity of three new selective COMT inhibitors in mice with a special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol Toxicol 69:64-70.
329. Törnwall M and Männistö PT (1993) Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur J Pharmacol 250:77-84.
330. Tunnicliff G and Ngo TT (1983) Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues. Int J Biochem 15: 733-738.
331. Tuomainen P, Törnwall M and Männistö PT (1996) Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: A microdialysis study in anaesthetized rats. Pharmacol Toxicol 78:392-396.
332. Ulmanen I and Lundström K (1991) Cell-free synthesis of rat and human catechol-O-methyltransferase: insertion of the membrane bound form into microsomal membranes in vitro. Eur J Biochem 202:1013-1020.
333. Ulmanen I, Peränen J, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Bernasconi L, Aubry JP and Lundström K (1997) Expression and intracellular localization of catechol O-methyltransferase in transfected mammalian cells. Eur J Biochem 243:452-459.
334. van Aswegen CH, Purdy RH and Wittliff JL (1989) Binding of 2-hydroxyestradiol and 4-hydroxyestridiol to estrogen receptor human breast cancers. J Steroid Biochem 32:485-492.
335. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR and Lachman HM (1997) High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74:439-442.
336. Vidgren J and Ovaska M (1997) Structural aspects in the inhibitor design of catechol O-methyltransferase, in Structure-based Drug Design (Veerapandian P ed) pp 343-363, Marcel Dekker, Inc., New York.
337. Vidgren J, Ovaska M, Tenhunen J, Tilgmann C, Lotta T and Männistö PT (1999) Catechol O-methyltransferase, in Structure and Function of AdoMet-dependent Methyltransferases (Cheng X and Blumenthal RM eds) pp 55-91, World Scientific, Singapore.
338. Vidgren J, Svensson LA and Liljas A (1994) Crystal structure of catechol O-methyltransferase. Nature (Lond) 368:354-358.
339. Vidgren J, Tilgmann C, Lundström K and Liljas A (1991) Crystallization and preliminary X-ray investigation of a recombinant form of rat catechol-O-methyltransferase. Prot Struct Funct Gen 11:233-236.
340. Vieira-Coelho MA and Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117:516-520.
341. Vieira-Coelho MA and Soares-da-Silva P (1998) Alpha(2)-adrenoceptors mediate the effect of dopamine on adult rat jejunal electrolyte transport. Eur J Pharmacol 356:59-65.
342. Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S and Von Sprecher G (1990a) CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn-Schmiedeberg's Arch Pharmacol 342:305-311.
343. Waldmeier PC, Buchle AM and Steulet AF (1993) Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylases by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol 45:2417-2424.
344. Waldmeier PC, De Herdt P and Maitre L (1990b) Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-DOPA in the rat. J Neural Transm Suppl 32:381-386.
345. Waldmeier PC and Feldtrauer J-J (1987) On the role of O-methylation in the metabolism of S-adenosylmethionine in rat brain. Biochem Pharmacol 36:2855-2861.
346. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D and Pedder S (1997) Tolcapone ID stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 49:665-671.
347. Wei J, Ramchand CN, Clark A and Hemmings GP (1996) A study of enzymes involved in catecholamine metabolism in parents of patients with schizophrenia. Schizophr Res 19:27-32.
348. Weinshilboum R and Raymond FA (1977) Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Med Genet 29:125-135.
349. Weinshilboum RM, Raymond FA and Frohnauer M (1979) Monogenic inheritance of catechol-O-methyltransferase activity in the rat: Biochemical and genetic studies. Biochem Pharmacol 28:1239-1247.
350. Weisz J (1991) Metabolism of estrogens by target cells: Diversification and amplification of hormone action and the catechol estrogen hypothesis, in New Biology of Steroid Hormones (Hochberg RB and Naftolin F eds) pp 101-112, Raven Press, New York.
351. Weisz J (1994) Biogenesis of catecholestrogens: Metabolic activation of estrogens by phase I enzymes. Polycyclic Arom Comp 6:241-251.
352. Weisz J, Clawson GA and Creveling CR (1998a) Biogenesis and inactivation of catecholestrogens, in Advances in Pharmacology. Catecholamines: Bridging Basic Science with Clinical Medicine (Goldstein D, Eisenhofer G and MaCarty R eds) pp 828-833, Academic Press, San Diego.
353. Weisz J, FritzWolz G, Clawson GA, Benedict CM, Abendroth C and Creveling CR (1998b) Induction of nuclear catechol-O-methyltransferase by estrogens in hamster kidney: Implications for estrogen-induced renal cancer. Carcinogenesis 19: 1307-1312.
354. Welsh MD, Ved N and Waters CH (1995) Improving quality of life in Parkinson's disease: An experimental study of tolcapone (Abstract). Qual Life Res 4:503.
355. Wikberg T and Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog. Drug Metab Dispos 21:325-333.
356. 14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. Eur J Drug Metab Pharmacokinet 19:125-135.
357. Wikberg T, Vuorela A, Ottoila P and Taskinen J (1993) Identification of major metabolites of the catechol O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92.
358. Winqvist R, Lundström K, Salminen M, Laatikainen M and Ulmanen I (1992) The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogen Cell Genet 59:253-257.
359. Woodard RW, Tsai M-D, Floss HG, Crooks PA and Coward JK (1980) Stereochemical course of the transmethylation catalyzed by catechol-O-methyltransferase. J Biol Chem 258:9124-9127.
360. Xie T, Ho SL, Li LSW and Ma OCK (1997) G/A(1947) polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 12:426-427.
361. Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N and Kanazawa I (1997) Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm Gen Sect 104:229-236.
362. Yassin MS, Cheng H, Ekblom J and Oreland L (1998) Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain. Neurochem Int 32:53-59.
363. Yoritaka A, Hattori N, Yoshino H and Mizuno Y (1997) Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan. J Neural Transm Gen Sect 104:1313-1317.
364. Yuan J-M, Yu MC, Ross RK, Gao YT and Henderson BE (1988) Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 48:1949-1953.
365. Zhu BT and Conney AH (1998) Functional role of estrogen metabolism in target cells: Review and perspectives. Cardnogenesis 19:1-27.
366. Zhu BT and Liehr JG (1996) Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2-and 4-hydroxyestradiol by quercetin. J Biol Chem 271:1357-1363.
367. Zhu BT, Roy D and Liehr JG (1993) The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology 132:577-583.
368. Zürcher G, Colzi A and Da Prada M (1990a) Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 32:375-380.
369. Zürcher G, Dingemanse J and Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings, in New Developments in Therapy of Parkinson's Disease (Agnoli A and Campanella G eds) pp 37-43, John Libbey CIC s.r.l., Rome.
370. Zürcher G, Dingemanse J and Da Prada M (1993) Potent COMT inhibition by Ro-40-7592 in the periphery and in the brain: Preclinical and clinical findings. Adv Neurol 60: 641-647.
371. Zürcher G, Da Prada M and Dingemanse J (1996) Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. Biomed Chromatogr 10:32-36.
372. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R and Da Prada M (1990b) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: A pharmacological study in rats. Adv Neurol 53: 497-503.